CRISPR Therapeutics AG (CRSP) EV to CFO (2016 - 2026)

CRISPR Therapeutics AG has disclosed EV to CFO across 11 years of filings, most recently posting 34.82 for Q2 2026.

• In Q2 2026, EV to CFO fell 53.86% year-over-year to 34.82; the TTM figure through Jun 2026 stood at 7.87 (up 0.87% YoY), while the FY2025 annual figure was 8.85, up 14.11% from the prior year.
• EV to CFO came in at 34.82 for Q2 2026 at CRISPR Therapeutics AG, down from 19.68 in the prior quarter.
• In the past five years, EV to CFO ranged from a high of 191.37 in Q1 2023 to a low of 49.25 in Q3 2025.
• Average EV to CFO over 5 years is 11.83, with a median of 21.4 recorded in 2023.
• Year-over-year, EV to CFO tumbled 255.59% in 2022 and soared 1081.69% in 2023.
• Over 5 years, EV to CFO stood at 12.14 in 2022, then tumbled by 184.32% to 34.53 in 2023, then climbed by 14.85% to 29.4 in 2024, then fell by 12.19% to 32.99 in 2025, then declined by 5.57% to 34.82 in 2026.
• Per Business Quant data, the three most recent EV to CFO figures were 34.82 in Q2 2026, 19.68 in Q1 2026, and 32.99 in Q4 2025.